Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis

Optimal management of atopic dermatitis requires a comprehensive assessment of response to treatment in order to inform therapeutic decisions. In a real-world setting, successful response to atopic dermatitis treatment is measured by sustained improvements in signs, symptoms, and quality of life. Po...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jonathan I. Silverberg, Eric L. Simpson, Mark Boguniewicz, Marjolein S. De Bruin-Weller, Peter Foley, Yoko Kataoka, Gaëlle Bégo-Le-Bagousse, Zhen Chen, Brad Shumel, Jingdong Chao, Ana B. Rossi
Formato:	article
Lenguaje:	EN
Publicado:	Society for Publication of Acta Dermato-Venereologica 2021
Materias:	atopic dermatitis treat-to-target responder Eczema Area and Severity Index pruritus Dermatology Life Quality Index Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/533ab1ccbbd94b2b91b12b77601f1e28
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:533ab1ccbbd94b2b91b12b77601f1e28
record_format	dspace
spelling	oai:doaj.org-article:533ab1ccbbd94b2b91b12b77601f1e282021-11-10T12:26:33ZDupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis10.2340/actadv.v101.3070001-55551651-2057https://doaj.org/article/533ab1ccbbd94b2b91b12b77601f1e282021-11-01T00:00:00Zhttps://medicaljournalssweden.se/actadv/article/view/307https://doaj.org/toc/0001-5555https://doaj.org/toc/1651-2057Optimal management of atopic dermatitis requires a comprehensive assessment of response to treatment in order to inform therapeutic decisions. In a real-world setting, successful response to atopic dermatitis treatment is measured by sustained improvements in signs, symptoms, and quality of life. Post-hoc analyses of a 1-year, randomized, double-blinded, placebo- controlled trial (NCT02260986) of dupilumab with concomitant topical corticosteroids in 421 adults with moderate-to-severe atopic dermatitis (of whom 315/106 received placebo/dupilumab (of whom 315 received placebo and 106 received dupilumab) was performed to assess the proportion of responders to dupilumab through a multidimensional composite endpoint. At 6-months, 80.2% of dupilumab-treated vs 40.0% placebo patients (p < 0.0001) achieved improvement in signs (Eczema Area and Severity Index ≤ 7), symptoms (worst itch score ≤ 4), or quality of life (Dermatology Life Quality Index ≤5), representative of minimal/clear atopic dermatitis. All 3 endpoints, indicative of no/minimal atopic dermatitis, were achieved by 44.3% of dupilumab-treated vs 10.2% placebo patients (p < 0.0001) and sustained through 1 year. Dupilumab treatment provided sustained clinically meaningful improvement in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis. Jonathan I. SilverbergEric L. SimpsonMark BoguniewiczMarjolein S. De Bruin-WellerPeter FoleyYoko KataokaGaëlle Bégo-Le-BagousseZhen ChenBrad ShumelJingdong ChaoAna B. RossiSociety for Publication of Acta Dermato-Venereologicaarticleatopic dermatitistreat-to-targetresponderEczema Area and Severity IndexpruritusDermatology Life Quality IndexDermatologyRL1-803ENActa Dermato-Venereologica, Vol 101, Iss 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	atopic dermatitis treat-to-target responder Eczema Area and Severity Index pruritus Dermatology Life Quality Index Dermatology RL1-803
spellingShingle	atopic dermatitis treat-to-target responder Eczema Area and Severity Index pruritus Dermatology Life Quality Index Dermatology RL1-803 Jonathan I. Silverberg Eric L. Simpson Mark Boguniewicz Marjolein S. De Bruin-Weller Peter Foley Yoko Kataoka Gaëlle Bégo-Le-Bagousse Zhen Chen Brad Shumel Jingdong Chao Ana B. Rossi Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
description	Optimal management of atopic dermatitis requires a comprehensive assessment of response to treatment in order to inform therapeutic decisions. In a real-world setting, successful response to atopic dermatitis treatment is measured by sustained improvements in signs, symptoms, and quality of life. Post-hoc analyses of a 1-year, randomized, double-blinded, placebo- controlled trial (NCT02260986) of dupilumab with concomitant topical corticosteroids in 421 adults with moderate-to-severe atopic dermatitis (of whom 315/106 received placebo/dupilumab (of whom 315 received placebo and 106 received dupilumab) was performed to assess the proportion of responders to dupilumab through a multidimensional composite endpoint. At 6-months, 80.2% of dupilumab-treated vs 40.0% placebo patients (p < 0.0001) achieved improvement in signs (Eczema Area and Severity Index ≤ 7), symptoms (worst itch score ≤ 4), or quality of life (Dermatology Life Quality Index ≤5), representative of minimal/clear atopic dermatitis. All 3 endpoints, indicative of no/minimal atopic dermatitis, were achieved by 44.3% of dupilumab-treated vs 10.2% placebo patients (p < 0.0001) and sustained through 1 year. Dupilumab treatment provided sustained clinically meaningful improvement in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis.
format	article
author	Jonathan I. Silverberg Eric L. Simpson Mark Boguniewicz Marjolein S. De Bruin-Weller Peter Foley Yoko Kataoka Gaëlle Bégo-Le-Bagousse Zhen Chen Brad Shumel Jingdong Chao Ana B. Rossi
author_facet	Jonathan I. Silverberg Eric L. Simpson Mark Boguniewicz Marjolein S. De Bruin-Weller Peter Foley Yoko Kataoka Gaëlle Bégo-Le-Bagousse Zhen Chen Brad Shumel Jingdong Chao Ana B. Rossi
author_sort	Jonathan I. Silverberg
title	Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
title_short	Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
title_full	Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
title_fullStr	Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
title_full_unstemmed	Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
title_sort	dupilumab provides rapid and sustained clinically meaningful responses in adults with moderate-to-severe atopic dermatitis
publisher	Society for Publication of Acta Dermato-Venereologica
publishDate	2021
url	https://doaj.org/article/533ab1ccbbd94b2b91b12b77601f1e28
work_keys_str_mv	AT jonathanisilverberg dupilumabprovidesrapidandsustainedclinicallymeaningfulresponsesinadultswithmoderatetosevereatopicdermatitis AT ericlsimpson dupilumabprovidesrapidandsustainedclinicallymeaningfulresponsesinadultswithmoderatetosevereatopicdermatitis AT markboguniewicz dupilumabprovidesrapidandsustainedclinicallymeaningfulresponsesinadultswithmoderatetosevereatopicdermatitis AT marjoleinsdebruinweller dupilumabprovidesrapidandsustainedclinicallymeaningfulresponsesinadultswithmoderatetosevereatopicdermatitis AT peterfoley dupilumabprovidesrapidandsustainedclinicallymeaningfulresponsesinadultswithmoderatetosevereatopicdermatitis AT yokokataoka dupilumabprovidesrapidandsustainedclinicallymeaningfulresponsesinadultswithmoderatetosevereatopicdermatitis AT gaellebegolebagousse dupilumabprovidesrapidandsustainedclinicallymeaningfulresponsesinadultswithmoderatetosevereatopicdermatitis AT zhenchen dupilumabprovidesrapidandsustainedclinicallymeaningfulresponsesinadultswithmoderatetosevereatopicdermatitis AT bradshumel dupilumabprovidesrapidandsustainedclinicallymeaningfulresponsesinadultswithmoderatetosevereatopicdermatitis AT jingdongchao dupilumabprovidesrapidandsustainedclinicallymeaningfulresponsesinadultswithmoderatetosevereatopicdermatitis AT anabrossi dupilumabprovidesrapidandsustainedclinicallymeaningfulresponsesinadultswithmoderatetosevereatopicdermatitis
_version_	1718439986592743424

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis

Ejemplares similares